Applied DNA Secures Significant Follow-on Order from IVD Manufacturer

Applied DNA Sciences, Inc. (NASDAQ:APDN) announced it has received a follow-on order worth over $500,000 for Linea™ DNA from a global manufacturer of in vitro diagnostics (IVDs). The order, part of a long-standing supply agreement for non-therapeutic Linea DNA for cancer diagnostic tests, will be fulfilled across four quarterly shipments in 2025.

Dr. James A. Hayward, president and CEO, remarked on the stability and growth shown by this recurring order, which arrives less than a year since the previous one. "Having serviced this customer with multiple gram-scale orders over nearly a decade, we believe we are well positioned to meet the diagnostic industry's growing need for DNA," he said.

Linea™ DNA is produced using the Company's proprietary polymerase chain reaction (PCR) based manufacturing platform, serving as an alternative to plasmid-based DNA. It is applicable for nucleic acid-based therapies, including mRNA therapies, DNA vaccines, and various diagnostic tests.